Communiqué de presse – Strasbourg, le 3 mars 2026 ALBUPAD sécurise 1,3M€ auprès d’Alsace Business Angels, Yeast et de Bpifrance pour développer sa technologie de libération prolongée au service des thérapies innovantes ALBUPAD, startup deeptech strasbourgeoise qui développe une plateforme … Read More
ALBUPAD provides a foundational platform for powering next-generation therapeutics
ALBUPAD invented a natural, proprietary biomaterial that leverages the intrinsic qualities of albumin
– including biocompatibility, biodegradability, tumor tropism, and inherent imaging visibility
– while eliminating the need for synthetic targeting ligands , toxic excipients, or added imaging agents.
Beyond biological and regulatory advantages, the ALBUPAD biomaterials offer exceptional versatility of formulation and tunable forms.
TECHNOLOGY
ALBUPAD technology was developed to produce
the next generation of albumin based materials
Our targeted applications are mainly
drug delivery (human or veterinary use) and tissue engineering
We developed a green approach that allows
the production of materials entirely made of albumin
Lire la vidéo
Our team brings strong expertise in drug delivery and advanced formulation, spanning formulation design, physicochemical characterization, encapsulation, vectorization, and preclinical development.
You can contact us for any questions by sending an email
OUR LATEST NEWS
ALBUPAD Lauréat I-Lab
Lire le communiqué de la SARR en pdf SATT CONECTUS
Révolutionner la délivrance des médicaments
Lire le document en pdf INSERM Magazine Lire l’article en ligne INSERM Magazine